Immunosuppression and infection prophylaxis after lung transplantation;Immunsuppression und Infektionsprophylaxe nach Lungentransplantation

Pneumologie

Volumn 65, Issue 2, 2011, Pages 94-102

  Neurohr, C ^a   Behr, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; RAPAMYCIN;

ARTICLE; ASPERGILLOSIS; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPH NODE IRRADIATION; PNEUMOCYSTIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PUVA; SURVIVAL RATE; SURVIVAL TIME;

EID: 79651475010     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0030-1255762     Document Type: Article

References (82)

1. Christie J D., Edwards L B., Aurora P et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009 28 1031-1049
2. Palmer S M., Miralles A P., Lawrence C M. et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest 1999 116 127-133
3. Wiebe K, Harringer W, Wahlers T et al. ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference? Transplant Proc 1998 30 1517-1518
4. Wain J C., Wright C D., Ryan D P. Induction immunosuppression for lung transplantation with OKT3. Ann Thorac Surg 1999 67 187-193
5. Brock M V., Borja M C., Ferber L et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001 20 1282-1290
6. Abramowicz D, Schandene L, Goldman M et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989 47 606-608
7. Ding I B., Baumgartner R A., Schwaiblmair M, Behr J. Administration of anti-interleukin-2Ralpha monoclonal antibody in bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2003 75 1767-1769
8. Burton C M., Andersen C B., Jensen A S. et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2006 25 638-647
9. Garrity E R. Jr., Villanueva J, Bhorade S M. et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001 71 773-777
10. McCurry K R., Iacono A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005 130 528-537
11. van Loenhout K C., Groves S C., Galazka M et al. Early outcomes using alemtuzumab induction in lung transplantation. Interact Cardiovasc Thorac Surg 2010 10 190-194 [Epub 2009 Nov 25]
12. Hoffmeyer F, Hoeper M M., Spiekerkotter E et al. Azathioprine withdrawal in stable lung and heart/lung recipients receiving cyclosporine-based immunosuppression. Transplantation 2000 70 522-525
13. Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg 2009 35 1045-1055 [Epub 2009 Apr 5]
14. Borel J F., Feurer C, Gubler H U., Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976 6 468-475
15. Levy G, Thervet E, Lake J, Uchida K. Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation 2002 73 (9 Suppl) 12-18
16. Nemati E, Einollahi B, Taheri S et al. Cyclosporine trough (c0) and 2-hour postdose (c2) levels: which one is a predictor of graft loss? Transplant Proc 2007 39 1223-1224
17. Glanville A R., Morton J M., Aboyoun C L. et al. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation. J Heart Lung Transplant 2004 23 1170-1174
18. Glanville A R., Aboyoun C L., Morton J M. et al. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant 2006 25 928-934
19. Taylor J L., Palmer S M. Critical care perspective on immunotherapy in lung transplantation. J Intensive Care Med 2006 21 327-344
20. Ragette R, Kamler M, Weinreich G et al. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant 2005 24 1315-1319
21. Knoop C, Thiry P, Saint-Marcoux F et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005 5 1477-1482
22. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005 24 119-130
23. Keenan R J., Konishi H, Kawai A et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995 60 580-584
24. Treede H, Klepetko W, Reichenspurner H, et al.; Munich and Vienna Lung Transplant Group. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001 20 511-517
25. Zuckermann A, Reichenspurner H, Birsan T et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003 125 891-900
26. Reichenspurner H, Glanville A, Christina A, et al. and European and Australian Investigators in Lung Transplantation. Complete 3 Year Analysis of a Prospective Randomized International Multi-Center Investigator Driven Study Comparing Tacrolimus and Cyclosporin A, Both in Combination with MMF and Steroids after Lung Transplantation in 249 Patients. J Heart Lung Transplant 2008 27 S205-S206
27. Hachem R R., Yusen R D., Chakinala M M. et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007 26 1012-1018
28. Starnes V A. Heart-lung transplantation: an overview. Cardiol Clin 1990 8 159-168
29. Azzola A, Havryk A, Chhajed P et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004 77 275-280
30. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998 66 507-515
31. Mathew T H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998 65 1450-1454
32. Palmer S M., Baz M A., Sanders L et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001 71 1772-1776
33. McNeil K, Glanville A R., Wahlers T et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006 81 998-1003
34. Wali R K., Mohanlal V, Ramos E et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007 7 1572-1583
35. Fairbanks K D., Eustace J A., Fine D et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003 9 1079-1085
36. Snell G I., Levvey B J., Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002 21 540-546
37. Groetzner J, Wittwer T, Kaczmarek I et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006 81 355-360
38. Venuta F, De Giacomo T, Rendina E A. et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004 78 1940-1943
39. Snell G I., Levvey B J., Chin W et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc 2001 33 1084-1085
40. Ussetti P, Laporta R, de Pablo A et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 2003 35 1974-1977
41. King-Biggs M B., Dunitz J M., Park S J. et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003 75 1437-1443
42. Groetzner J, Kur F, Spelsberg F, et al.; Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004 23 632-638
43. Chhajed P N., Dickenmann M, Bubendorf L et al. Patterns of pulmonary complications associated with sirolimus. Respiration 2006 73 367-374
44. Bhorade S M., Ahya V, Kotloff R et al. Long Term Follow-Up in the AIRSAC Trial, a Multicenter Randomized Clinical Trial in Lung Transplant Recipients. J Heart and Lung Transplant 2009 28 S119-S120
45. Neumayer H H. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 2005 79 S72-S75
46. Snell G I., Valentine V G., Vitulo P, et al.; RAD B159 Study Group. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006 6 169-177
47. Strueber M, Stefan F, Simon A R. et al. Everolimus Versus Mycophenolatemofetil in De Novo Immunosuppression after Lung Transplantation - Interims Analysis of a Prospective, Randomized, Clinical Trial. J Heart and Lung Transplant 2008 27 205
48. Gullestad L, Iversen M, Mortensen S A. et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010 89 864-872
49. Otton J, Hayward C S., Keogh A M. et al. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant 2009 28 104-106 [Epub 2008 Dec 12]
50. Pratap B, Abraham G, Srinivas C N., Bhaskar S. Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. Saudi J Kidney Dis Transpl 2007 18 609-612
51. Morton J M., Williamson S, Kear L M. et al. Therapeutic drug monitoring of prednisolone after lung transplantation. J Heart Lung Transplant 2006 25 557-563
52. Borro J M., Sola A, De la Torre M et al. Steroid withdrawal in lung transplant recipients. Transplant Proc 2005 37 3991-3993
53. Shitrit D, Bendayan D, Sulkes J et al. Successful steroid withdrawal in lung transplant recipients: result of a pilot study. Respir Med 2005 99 596-601
54. Keogh A M., Arnold R H., Macdonald P S. et al. A randomized trial of tacrolimus (FK506) versus total lymphoid irradiation for the control of repetitive rejection after cardiac transplantation. J Heart Lung Transplant 2001 20 1331-1334
55. Diamond D A., Michalski J M., Lynch J P., Trulock E P. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys 1998 41 795-800
56. Fisher A J., Rutherford R M., Bozzino J et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005 5 537-543
57. Verleden G M., Lievens Y, Dupont L J. et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplant Proc 2009 41 1816-1820
58. Astor T L., Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg 2003 7 20-24
59. Morrell M R., Despotis G J., Lublin D M. et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010 29 424-431 [Epub 2009 Oct 22]
60. Benden C, Speich R, Hofbauer G F. et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008 86 1625-1627
61. Williams T J., Verleden G M. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med 2005 172 657-659
62. Verleden G M., Dupont L J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004 77 1465-1467
63. Vanaudenaerde B M., Meyts I, Vos R et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008 32 832-843
64. Gottlieb J, Szangolies J, Koehnlein T et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008 85 36-41
65. Vos R, Vanaudenaerdea B M., Schoonisa A et al. Azithromycin for Bronchiolitis Obliterans Syndrome after Lung Transplantation. J Heart and Lung Transplant 2010 29 S94
66. Iacono A T., Corcoran T E., Griffith B P. et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004 23 384-390
67. Iacono A T., Johnson B A., Grgurich W F. et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006 354 141-150
68. Ide N, Nagayasu T, Matsumoto K et al. Efficacy and safety of inhaled tacrolimus in rat lung transplantation. J Thorac Cardiovasc Surg 2007 133 548-553
69. Behr J, Zimmermann G, Baumgartner R, et al.; Munich Lung Transplant Group. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv 2009 22 121-130
70. Sarahrudi K, Estenne M, Corris P et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004 127 1126-1132
71. Jordan S C., Quartel A W., Czer L S. et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998 66 800-805
72. Bhorade S M., Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009 6 47-53
73. Fishman J A. Infection in solid-organ transplant recipients. N Engl J Med 2007 357 2601-2614
74. Remund K F., Best M, Egan J J. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009 6 94-100
75. Avery R K., Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008 8 9-14 [Epub 2007 Dec 18]
76. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 82 1052-1059
77. Hodson E M., Craig J C., Strippoli G F., Webster A C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008 16 CD003774
78. Fishman J A., Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007 21 149-158
79. Weigt S S., Elashoff R M., Huang C et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009 9 1903-1911 [Epub 2009 May 13]
80. Sola A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med 2009 15 243-253
81. Campos S, Caramori M, Teixeira R et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc 2008 40 822-824
82. Hafkin J, Blumberg E. Infections in lung transplantation: new insights. Curr Opin Organ Transplant 2009 14 483-487